Dietary Butyrate Enhances Anti-PD-1 Efficacy in NSCLC via Gut Microbiome Modulation
Dietary supplementation with butyrate enhances anti-tumor activity and improves the efficacy of α PD-1 therapy in mice, linked to immune cell modulation.
Phase III
non-small cell lung cancer (NSCLC)
Status
Active
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
The discovery that dietary butyrate can enhance the efficacy of PD-1 inhibitors presents a significant opportunity for pharma companies to innovate their immunotherapy strategies. This could lead to the development of adjunct therapies that leverage dietary interventions, potentially improving patient outcomes and market competitiveness.
Recommended action
Humanexa recommends Investigate.
Analysis
Monitor ongoing studies that investigate dietary interventions in combination with immunotherapy in NSCLC and other cancers.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.